Fig. 1

Distribution and co-occurrence of recurrent driver genomic alterations. Oncoprint plots showed genes altered in more than 5% of breast cancers samples. a Primary tumors (n = 106). b Recurrences (n = 82). Each gene was reported in rows; each case was reported in columns. Significant co-occurrent and recurrent copy number gains involved CCND1, FGF19, and FGF3 genes (p value < 0.001 and q < 0.01, according to mutual exclusivity analysis). Oncoprinter tool - cBioportal (https://www.cbioportal.org/oncoprinter) was used to create graphs and perform mutual exclusivity analysis